ABCSG 18: Monoclonal antibody increases disease-free survival in breast cancer
Wednesday, December 9, 2015 - 13:38
in Health & Medicine
Giving a monoclonal antibody (denosumab) as adjuvant therapy with aromatase inhibitors in postmenopausal, hormone-receptor-positive breast cancer patients reduces the relapse rate by 18%. This is the central finding of the ABCSG 18 breast cancer study regarding disease-free survival.